Nathan Dowden

Nathan Dowden

Fortune : 1 M $ au 30/06/2026

56 ans
Commercial Services
Consumer Services
Health Technology

Profil

Nathan J.
Dowden
is President & Chief Operating Officer at Entrada Therapeutics, Inc. since 2024, with employment at Entrada Therapeutics, Inc. starting in 2019.
Former positions include Managing Director at Huron Consulting Group, Inc. from 2014 to 2016; Managing Director at Frankel Group LLC; Senior Consultant at Ernst & Young LLP; Principal at G.D.
Searle & Co., Inc.; Analyst at CIGNA HealthCare, Inc. from 2013 to 2019; and Senior VP-Strategy & Corporate Development at Rubius Therapeutics, Inc. from 2016 to 2019.
Education includes undergraduate studies at the University of Connecticut and an MBA from The University of Chicago Booth School of Business.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
04/05/2026 198 588 ( 0,51 % ) 1 M $ 30/06/2026

Postes actifs de Nathan Dowden

SociétésPosteDébut
ENTRADA THERAPEUTICS, INC. President 01/01/2024

Anciens postes connus de Nathan Dowden

SociétésPosteFin
RUBIUS THERAPEUTICS Corporate Officer/Principal 25/07/2019
Corporate Officer/Principal 01/01/2019
HURON CONSULTING GROUP INC. Corporate Officer/Principal 01/03/2016
Frankel Group LLC
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Nathan Dowden

Formation de Nathan Dowden

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

22

Relations au 1er degré

9

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées9

Commercial Services

Commercial Services

Process Industries

Consumer Services

Health Services

Consumer Services

Health Technology

Health Technology

Frankel Group LLC

  1. Bourse
  2. Insiders
  3. Nathan Dowden
🔇